Fenretinide in Treating Patients With Recurrent Small Cell Lung Cancer

NCT00009971 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

32

Enrollment

NIH

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: fenretinide

Sponsor

National Cancer Institute (NCI)